SCHEMBL3949487

SCHEMBL3949487

COCc1ccc(C(=O)N(C)C)cn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.43
ALDH1A1 P00352 4/20 0.43
HPGD P15428 3/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
BRD4 O60885 1/20 0.39
HCAR3 P49019 1/20 0.38
CYP3A4 P08684 6/20 0.38
TDP1 Q9NUW8 2/20 0.38
HSD17B10 Q99714 4/20 0.37
CYP1A2 P05177 4/20 0.37
ALOX15 P16050 3/20 0.37
TSHR P16473 3/20 0.37
CLK4 Q9HAZ1 2/20 0.37
CYP2D6 P10635 2/20 0.37
TBXAS1 P24557 1/20 0.37
USP7 Q93009 1/20 0.37
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
CYP2C19 P33261 2/20 0.37
MAOB P27338 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20392400 0.84 KMT2A (0.42) KMT2AALDH1A1HPGDSMN1; SMN2HCAR3
SCHEMBL31003231 0.83 L3MBTL1 (0.43) KMT2AALDH1A1HPGDSMN1; SMN2HCAR3
SCHEMBL14480242 0.83 L3MBTL1 (0.43) KMT2AALDH1A1HPGDSMN1; SMN2HCAR3
SCHEMBL31606793 0.81 KMT2A (0.47) KMT2AALDH1A1HPGDSMN1; SMN2HCAR3
SCHEMBL1680993 0.81 MAPT (0.53) ALDH1A1HPGDHCAR3HSD17B10CYP1A2
SCHEMBL15709844 0.81 KMT2A (0.42) KMT2AALDH1A1HPGDSMN1; SMN2BRD4
SCHEMBL23387618 0.80 KMT2A (0.46) KMT2AALDH1A1HPGDSMN1; SMN2HCAR3
SCHEMBL1439028 0.80 MAPK1 (0.59) KMT2AALDH1A1TDP1TSHRKDM4E
SCHEMBL2818852 0.80 MAPT (0.51) ALDH1A1HPGDHCAR3HSD17B10CYP1A2
SCHEMBL31480792 0.80 NNMT (0.57) SMN1; SMN2KDM4EMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7553845-B2 Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives SANOFI-AVENTIS (FR) 2009-06-30 US disclosed
US-7553845-B2 Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives SANOFI-AVENTIS (FR) 2009-06-30 US disclosed
US-7553845-B2 Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives SANOFI-AVENTIS (FR) 2009-06-30 US disclosed
US-20060199962-A1 Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives SANOFI-AVENTIS (FR) 2006-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199962-A1 Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives FGF1, FGF2, FGFR1 KMT2A 2957/4885ALDH1A1 724/4885HPGD 2089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.